The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | Rejuvinated CD8+ T-cells derived from iPSCs in the treatment of myeloma
Jooeun Bae, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses a study which investigated the use of induced pluripotent stem cells (iPSCs) as a tool to generate rejuvenated CD8+ T-cells and overcome antigen-specific T-cell exhaustion in the context of myeloma treatment. Dr Bae explains the methods used in this study, including details on the isolation of progenitor cells and the differentiation of these progenitor cells into highly functional BCMA-specific CD8+ cytotoxic T lymphocytes. Dr Bae then explains that the transcriptional regulators directing the differentiation of these cells were identified. To conclude, Dr Bae highlights the important framework that this study provides for future iPSC-based T-cell regenerative medicine, and the great implications this may have in the future of myeloma treatment. This interview took place at the 63rd ASH Annual Meeting and Exposition congress, Atlanta, GA, 2021.
